Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AgfiledCriticalBayer Schering Pharma Ag
Priority to CU20070204ApriorityCriticalpatent/CU23738B7/en
Publication of CU20070204A7publicationCriticalpatent/CU20070204A7/en
Publication of CU23738B7publicationCriticalpatent/CU23738B7/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente solicitud se refiere a nuevas formulaciones de medicamento de vardenafilo que se disuelven rápidamente en la boca y conducen a un aumento de la biodisponibilidad y a un desarrollo de la concentración en plasma de tipo meseta, así como a procedimientos para su preparación.The present application refers to new formulations of vardenafil medication that dissolve rapidly in the mouth and lead to an increase in bioavailability and a development of the plasma plateau concentration, as well as procedures for its preparation.
CU20070204A2007-08-302007-08-30
PHARMACEUTICAL FORMS WITH IMPROVED PHARMACOCINETIC PROPERTIES
CU23738B7
(en)
Pharmaceutical compositions comprising a first agent selected from the group consisting of i) an anti-inflammatory agent, ii) acetaminophen, iii) phenacetin, iv) tramadol, and a second agent; use of said compositions to treat proliferative diseases including cancer.
Method for the preparation of a pharmaceutical composition containing a thermostable oxygen carrier; pharmaceutical composition containing a highly purified and thermostable oxygen carrier.
Tamarind seed polysaccharide for use in the treatment of infectious diseases; pharmaceutical and / or anti-inflammatory dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide.